Headlines about Mersana Therapeutics (NASDAQ:MRSN) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mersana Therapeutics earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.5218021214808 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

MRSN has been the subject of several research reports. Cowen and Company initiated coverage on Mersana Therapeutics in a research note on Monday, July 24th. They set an “outperform” rating for the company. J P Morgan Chase & Co initiated coverage on Mersana Therapeutics in a research note on Monday, July 24th. They set an “overweight” rating and a $23.00 target price for the company. Leerink Swann initiated coverage on Mersana Therapeutics in a research note on Monday, July 24th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of Mersana Therapeutics in a research note on Monday, July 24th.

Mersana Therapeutics (MRSN) traded down 2.07% during midday trading on Thursday, hitting $17.51. The stock had a trading volume of 67,624 shares. The firm’s market cap is $397.70 million. The stock has a 50-day moving average of $14.94 and a 200-day moving average of $14.77. Mersana Therapeutics has a 52 week low of $12.71 and a 52 week high of $18.05.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Friday, August 11th. The company reported ($6.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by $5.77. The firm had revenue of $3.73 million during the quarter, compared to the consensus estimate of $3.33 million. Analysts forecast that Mersana Therapeutics will post ($6.59) EPS for the current fiscal year.

In other news, major shareholder M James Barrett purchased 1,000,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/31/mersana-therapeutics-mrsn-given-daily-media-sentiment-score-of-0-02.html.

About Mersana Therapeutics

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Receive News & Stock Ratings for Mersana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc. and related stocks with our FREE daily email newsletter.